Synolaki, 312 patient HCQ late treatment study: 24% lower mortality [p=0.27] https://c19p.org/synolaki
copied to clipboard
The Activin/Follistatin-axis is severely deregulated in COVID-19 and independently associated with in-hospital mortality
et al., medRxiv, doi:10.1101/2020.09.05.20184655 (Preprint)
Retrospective 117 patients, 58 HCQ showing lower mortality for HCQ patients.Version 1 of this paper stated: "HCQ, AZ, [and ...] were found to be independently associated with survival when treatment commenced at FACTCLINYCoD scores <3".
|
risk of death, 23.6% lower, RR 0.76, p = 0.27, treatment 21 of 98 (21.4%), control 60 of 214 (28.0%), NNT 15.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Synolaki et al., 9/5/2020, retrospective, Greece, Europe, preprint, 20 authors.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.